1. Market Research
  2. > Gastrointestinal Tumor - Pipeline Review, H2 2013

Gastrointestinal Tumor - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 47 pages

Gastrointestinal Tumor - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Gastrointestinal Tumor - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Gastrointestinal Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastrointestinal Tumor. Gastrointestinal Tumor - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gastrointestinal Tumor.
- A review of the Gastrointestinal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gastrointestinal Tumor pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Tumor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Tumor pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Gastrointestinal Tumor - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastrointestinal Tumor Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Gastrointestinal Tumor 7
Gastrointestinal Tumor Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Gastrointestinal Tumor Therapeutics - Products under Development by Companies 13
Companies Involved in Gastrointestinal Tumor Therapeutics Development 14
F. Hoffmann-La Roche Ltd. 14
Taiho Pharmaceutical Co., Ltd. 15
MacroGenics, Inc. 16
Nobelpharma Co., Ltd. 17
CritiTech, Inc. 18
Gastrointestinal Tumor - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
DG-3173 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
(tipiracil hydrochloride + trifluridine) - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
paclitaxel - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
bevacizumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
MGD-007 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Gastrointestinal Tumor Therapeutics - Drug Profile Updates 35
Gastrointestinal Tumor Therapeutics - Discontinued Products 42
Gastrointestinal Tumor Therapeutics - Dormant Products 43
Gastrointestinal Tumor - Product Development Milestones 44
Featured News and Press Releases 44
Aug 30, 2013: Detailed results of the phase III CLARINET study at the European Cancer Congress 2013 on 28 September 2013 44
Jul 11, 2013: Ipsen announces positive results from phase III CLARINET study of Somatuline Autogel 120mg in gastrointestinal and pancreatic neuroendocrine tumors 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47



List of Tables

Number of Products Under Development for Gastrointestinal Tumor, H2 2013 7
Products under Development for Gastrointestinal Tumor - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
Comparative Analysis by Early Clinical Stage Development, H2 2013 11
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
F. Hoffmann-La Roche Ltd., H2 2013 14
Taiho Pharmaceutical Co., Ltd., H2 2013 15
MacroGenics, Inc., H2 2013 16
Nobelpharma Co., Ltd., H2 2013 17
CritiTech, Inc., H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Assessment by Combination Products, H2 2013 20
Assessment by Stage and Route of Administration, H2 2013 22
Assessment by Stage and Molecule Type, H2 2013 24
Gastrointestinal Tumor Therapeutics - Drug Profile Updates 35
Gastrointestinal Tumor Therapeutics - Discontinued Products 42
Gastrointestinal Tumor Therapeutics - Dormant Products 43



List of Figures

Number of Products under Development for Gastrointestinal Tumor, H2 2013 7
Products under Development for Gastrointestinal Tumor - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Mid Clinical Stage Products, H2 2013 10
Early Clinical Stage Products, H2 2013 11
Pre-Clinical Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 19
Assessment by Combination Products, H2 2013 20
Assessment by Route of Administration, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 22
Assessment by Molecule Type, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 24



Companies Mentioned

F. Hoffmann-La Roche Ltd.
Taiho Pharmaceutical Co., Ltd.
MacroGenics, Inc.
Nobelpharma Co., Ltd.
CritiTech, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.